912 related articles for article (PubMed ID: 27168247)
1. Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.
Burton DR; Hangartner L
Annu Rev Immunol; 2016 May; 34():635-59. PubMed ID: 27168247
[TBL] [Abstract][Full Text] [Related]
2. Human Ig knockin mice to study the development and regulation of HIV-1 broadly neutralizing antibodies.
Verkoczy L; Alt FW; Tian M
Immunol Rev; 2017 Jan; 275(1):89-107. PubMed ID: 28133799
[TBL] [Abstract][Full Text] [Related]
3. Native-like Env trimers as a platform for HIV-1 vaccine design.
Sanders RW; Moore JP
Immunol Rev; 2017 Jan; 275(1):161-182. PubMed ID: 28133806
[TBL] [Abstract][Full Text] [Related]
4. Strategies for a multi-stage neutralizing antibody-based HIV vaccine.
Andrabi R; Bhiman JN; Burton DR
Curr Opin Immunol; 2018 Aug; 53():143-151. PubMed ID: 29775847
[TBL] [Abstract][Full Text] [Related]
5. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.
Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR
Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.
Sliepen K; Sanders RW
Expert Rev Vaccines; 2016; 15(3):349-65. PubMed ID: 26654478
[TBL] [Abstract][Full Text] [Related]
7. Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.
Moore PL; Gorman J; Doria-Rose NA; Morris L
Immunol Rev; 2017 Jan; 275(1):217-229. PubMed ID: 28133797
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Reh L; Magnus C; Kadelka C; Kühnert D; Uhr T; Weber J; Morris L; Moore PL; Trkola A
PLoS Pathog; 2018 Jan; 14(1):e1006825. PubMed ID: 29370298
[TBL] [Abstract][Full Text] [Related]
9. Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Sadanand S; Suscovich TJ; Alter G
Annu Rev Med; 2016; 67():185-200. PubMed ID: 26565674
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
11. Strategies for eliciting multiple lineages of broadly neutralizing antibodies to HIV by vaccination.
Mu Z; Haynes BF; Cain DW
Curr Opin Virol; 2021 Dec; 51():172-178. PubMed ID: 34742037
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
[TBL] [Abstract][Full Text] [Related]
13. Targeting broadly neutralizing antibody precursors: a naïve approach to vaccine design.
McGuire AT
Curr Opin HIV AIDS; 2019 Jul; 14(4):294-301. PubMed ID: 30946041
[TBL] [Abstract][Full Text] [Related]
14. Natural infection as a blueprint for rational HIV vaccine design.
van Haaren MM; van den Kerkhof TL; van Gils MJ
Hum Vaccin Immunother; 2017 Jan; 13(1):229-236. PubMed ID: 27649455
[TBL] [Abstract][Full Text] [Related]
15. Identification and specificity of broadly neutralizing antibodies against HIV.
McCoy LE; Burton DR
Immunol Rev; 2017 Jan; 275(1):11-20. PubMed ID: 28133814
[TBL] [Abstract][Full Text] [Related]
16. Challenges for structure-based HIV vaccine design.
Schief WR; Ban YE; Stamatatos L
Curr Opin HIV AIDS; 2009 Sep; 4(5):431-40. PubMed ID: 20048708
[TBL] [Abstract][Full Text] [Related]
17. The HIV-1 envelope glycoprotein structure: nailing down a moving target.
Ward AB; Wilson IA
Immunol Rev; 2017 Jan; 275(1):21-32. PubMed ID: 28133813
[TBL] [Abstract][Full Text] [Related]
18. Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity.
Hu JK; Crampton JC; Cupo A; Ketas T; van Gils MJ; Sliepen K; de Taeye SW; Sok D; Ozorowski G; Deresa I; Stanfield R; Ward AB; Burton DR; Klasse PJ; Sanders RW; Moore JP; Crotty S
J Virol; 2015 Oct; 89(20):10383-98. PubMed ID: 26246566
[TBL] [Abstract][Full Text] [Related]
19. Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Landais E; Moore PL
Retrovirology; 2018 Sep; 15(1):61. PubMed ID: 30185183
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a Prefusion HIV-1 Envelope Trimer in Complex with a Quaternary-Structure-Specific Antibody.
Cheng C; Pancera M; Bossert A; Schmidt SD; Chen RE; Chen X; Druz A; Narpala S; Doria-Rose NA; McDermott AB; Kwong PD; Mascola JR
J Virol; 2015 Dec; 90(6):2740-55. PubMed ID: 26719262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
